by Raynovich Rod | Apr 4, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update 4/7…Genmark Dx (GNMK) up 22% after hours on revised revenue guidance for 2020: Total revenues of $38.7M expected. Biotechs mainly in the red and big sell-off in plays below; other notable movers: VIR off 12.56%, CODX off 11.8%, MRNA off 7.56%. Gilead...
by Raynovich Rod | Mar 8, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
3/30 11;30a Major news on COVID-19 diagnostics spark rally. Abbott launches 5 minute test. ABT up 7.28% ,JNJ up 6.8%, all large caps up, IBB up 2.55, XBI up 1.61%. Risk reward still looks good for biotech by year-end 2020. See IBB 2 yr chart below. ======== 3/27 After...
by Raynovich Rod | Mar 2, 2020 | 2019 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools
Update-1 nice broad biotech rally on stimulus hopes with biotech now seen as possible solution https://www.barrons.com/articles/the-dow-is-up-900-points-after-congress-agrees-on-8-3-billion-package-to-battle-coronavirus-51583350527?mod=hp_LATEST XBI up over 3%to $93...
by Raynovich Rod | Feb 22, 2020 | Biopharmaceuticals, Macro
2/28 10:15a XBI down to $86 level. Looking today to see what to buy. Bought VCYT yesterday at $23+ GNMK up 39% to $5 handle. Diagnostic and tools sector could be the place to look for buys but stocks are extremely volatile—-but now one hour later up only 20%!!...
by Raynovich Rod | Feb 13, 2020 | 2009-2017 Life Science Portfolios, 2019 Rayno Biopharmaceuticals Portfolio
Update-2 Mid-day trading 2/21 NAZ down 1.14%-Biotech stocks held their levels on a down day. Most large cap Raygent focus stocks are in green: ABBV,BMY,GILD up 4%, RHHBY. Mid-caps are mixed but BMRN is up 5%. Healthcare sector was a leader up 0.1% ============...
by Raynovich Rod | Feb 11, 2020 | 2019 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Large Cap Biopharmaceutical Companies – Q1 2020 Update The IBB is at $122.69 near the 52 week high but short of 5 year high of $132.53 from Jy ’15. FWD PEs of sector are still lower than the market with S&P-500 at 18.9x. Good growth expected. Our Top...
by Raynovich Rod | Feb 6, 2020 | 2019 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-2 2/10…Rally has expanded to mid-caps:ALNY ACAD GWPH ICPT SRPT Etc. ======= Update-1 2/7. 2p …Abbvie (ABBV) Another one of our top large cap picks ABBV is up 6% o the $92 handle as of mid-day trading on earnings and Allergan acquisition. Full year...
by Raynovich Rod | Jan 31, 2020 | Biopharmaceuticals, Macro
Update-1 2/3…3:30p EST… Biopharma stocks firm up after a bad week Large caps are strong with Gilead Sciences (GILD) up over 5% on a story about an experimental antiviral therapy for coronavirus China. GILD is one of the leading antiviral companies for...
by Raynovich Rod | Jan 29, 2020 | medtech
New Buy Ideas for 2020-Biopharma and MedTech New Buy Idea -Glaukos (GKOS) for ophthalmic disease therapies If you have been reading my recent posts I have been cautious on adding new positions since the JPMorgan Healthcare Conference. After the nice Q4 run-up it would...
by Raynovich Rod | Jan 26, 2020 | Biopharmaceuticals
Update-2 1/30 a Mid-day trading- Bearish pattern emerging Many of our indicators have turned bearish: XBI down 1.8% under $90, red screen in mid-caps, large caps at lows for the day, IWM at day lows etc. Fears about coronavirus causing buyers strike? Risk-off, even...
Reuters Healthcare